


**CENTER FOR DRUG EVALUATION AND RESEARCH**

*APPLICATION NUMBER:*

**50-742 / S-001**

**CHEMISTRY REVIEW(S)**

<b>SUPPLEMENTAL NDA CHEMIST'S REVIEW # 1</b>		<b>1. ORGANIZATION</b> HFD-590	<b>2. NDA NUMBER</b> 50-742
<b>3. NAME AND ADDRESS OF APPLICANT (City and State)</b> Merck & Co., Inc. West Point, PA 19468-0004		<b>4. AF NUMBER</b>	
		<b>5. DOCUMENT(S) NUMBERS DATES</b> SCF-001 12/12/97	
<b>6. NAME OF DRUG</b> Stromectol® Tablets		<b>7. NONPROPRIETARY NAME</b> Ivermectin	
<b>8. SUPPLEMENT(S) PROVIDES FOR:</b> A new tablet strength (3 mg).		<b>9. AMENDMENTS AND OTHER DATES</b>	
<b>10. PHARMACOLOGICAL CATEGORY</b> Anthelmintic		<b>11. HOW DISPENSED</b> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> OTC	
<b>12. RELATED IND/NDA/DMF(s)</b>			
<b>13. DOSAGE FORM(S)</b> Tablet		<b>14. POTENCY (CIES)</b> 6 mg	
<b>15. CHEMICAL NAME</b> ≥90% 5-O-demethyl-22,23-dihydroavermectin A <sub>1a</sub> (A.K.A. 22,23-dihydroavermectin B <sub>1a</sub> ) and <10% 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro-25-(1-methylethyl) avermectin A <sub>1a</sub> (A.K.A. 22,23-dihydroavermectin B <sub>1b</sub> )  C <sub>48</sub> H <sub>74</sub> O <sub>14</sub> & C <sub>47</sub> H <sub>72</sub> O <sub>14</sub> M.W. 875.10 & 861.07    B <sub>1a</sub> , R = C <sub>2</sub> H <sub>5</sub> B <sub>1b</sub> , R = CH <sub>3</sub> >90% B <sub>1a</sub> , <10% B <sub>1b</sub>		<b>16. MEMORANDA</b> N/A	
<b>17. COMMENTS</b> This supplemental application provides for a new tablet strength (3 mg). In support of the new tablet strength, the applicant has provided descriptions of the composition, manufacturing process and controls, release and stability specifications, and analytical methods, and release test data on 6 lots and stability data on 3 lots. Comparative dissolution data and some stability data was not provided.			
<b>18. CONCLUSIONS AND RECOMMENDATIONS</b> Forward comments to firm.			
<b>19. REVIEWER</b>			
<b>NAME</b> John Smith		<b>SIGNATURE</b>	
		<b>DATE COMPLETED</b> mm/dd/yy	
<b>20. CONCURRENCE: HFD-590/NSchmuff</b>			
<b>DISTRIBUTION</b>	<input checked="" type="checkbox"/>	Original Jacket	<input checked="" type="checkbox"/> JSmith
	<input checked="" type="checkbox"/>	Division File	<input checked="" type="checkbox"/> NSchmuff
			<input checked="" type="checkbox"/> HFD-830/CChen
			<input checked="" type="checkbox"/> MO
			<input checked="" type="checkbox"/> CSO

**WITHHOLD** 5 **PAGE(S)**

Exemption 4

<b>SUPPLEMENTAL NDA CHEMIST'S REVIEW # 2</b>		<b>1. ORGANIZATION</b> HFD-590	<b>2. NDA NUMBER</b> 50-742	
<b>3. NAME AND ADDRESS OF APPLICANT (City and State)</b> Merck & Co., Inc. West Point, PA 19468-0004		<b>4. AF NUMBER</b>		
<b>6. NAME OF DRUG</b> Stromectol® Tablets		<b>7. NONPROPRIETARY NAME</b> Ivermectin		
<b>8. SUPPLEMENT(S) PROVIDES FOR:</b> A new tablet strength (3 mg).		<b>9. AMENDMENTS AND OTHER DATES</b> 10/07/98		
<b>10. PHARMACOLOGICAL CATEGORY</b> Anthelmintic	<b>11. HOW DISPENSED</b> <input checked="" type="checkbox"/> R <input type="checkbox"/> OTC	<b>12. RELATED IND/NDA/DMF(s)</b>		
<b>13. DOSAGE FORM(S)</b> Tablet	<b>14. POTENCY (CIES)</b> 6 mg			
<b>15. CHEMICAL NAME</b> ≥90% 5-O-demethyl-22,23-dihydroavermectin A <sub>1a</sub> (A.K.A. 22,23-dihydroavermectin B <sub>1a</sub> ) and <10% 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro-25-(1-methylethyl) avermectin A <sub>1a</sub> (A.K.A. 22,23-dihydroavermectin B <sub>1b</sub> )  C <sub>48</sub> H <sub>74</sub> O <sub>14</sub> & C <sub>47</sub> H <sub>72</sub> O <sub>14</sub> M.W. 875.10 & 861.07		<b>16. MEMORANDA</b> N/A		
<p>B<sub>1a</sub>, R = C<sub>2</sub>H<sub>5</sub>    B<sub>1b</sub>, R = CH<sub>3</sub> &gt;90% B<sub>1a</sub>, &lt;10% B<sub>1b</sub></p>				
<b>17. COMMENTS</b> This supplemental application provides for a new tablet strength (3 mg).  In support of the new tablet strength, the applicant has provided descriptions of the composition, manufacturing process and controls, release and stability specifications, and analytical methods, and release test data on 6 lots and stability data on 3 lots. Comparative dissolution data was provided in the 06/18/98 amendment.  In response to our fax on 09/23/98, the reduced testing schedule for annual stability batches was removed in the 10/07/98 amendment.				
<b>18. CONCLUSIONS AND RECOMMENDATIONS</b> Recommend: APPROVAL.				
<b>19. REVIEWER</b>				
<b>NAME</b> John Smith	<b>SIGNATURE</b>		<b>DATE COMPLETED</b> 09/17/98 & 10/08/98	
<b>20. CONCURRENCE: HFD-590/NSchmuff</b>				
<b>DISTRIBUTION</b>	<input checked="" type="checkbox"/>	Original Jacket	<input checked="" type="checkbox"/> JSmith	<input checked="" type="checkbox"/> MO
	<input checked="" type="checkbox"/>	Division File	<input checked="" type="checkbox"/> NSchmuff	<input checked="" type="checkbox"/> CSO
			<input checked="" type="checkbox"/> HFD-830/CChen	

**WITHHOLD 4 PAGE(S)**

Exemption 4